Advanced therapy medicinal products (ATMP) as products of innovative biotechnologies
Article Sidebar
Main Article Content
Abstract
Advanced therapy medicinal products (ATMP) offer hope for health benefits in all situations where traditional methods of therapy fail or cannot be used for various reasons. The main purpose of this article is to analyze the concept of innovation as applied to the biotechnologies employed in ATMP. In the analysis of the concept, five main contexts of meaning that contribute to its understanding will be distinguished: a change in the way of thinking about the available spectrum of medical procedures, the short time of recognition of technologies in the experimental and theoretical models, lack of clinical data in advance of used technologies, increase of technologies’ complexity and diversity of substrates used in them. The conducted analysis indicates the need to adopt an attitude of far-reaching caution in the evaluation of the safety of ATMP therapies in which innovative biotechnologies are used.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
By submitting his/her work to the Editorial Board, the author accepts, upon having his/her text recommended for publication, that Diametros applies the Attribution 4.0 International (CC BY 4.0) license to the works we publish. Under this license, authors agree to make articles legally available for reuse, without permission or fees. Anyone may read, download, copy, print, distribute or reuse these articles without asking prior permission from the publisher or the author, as long as the author and original source are properly cited. The author holds the copyright without any other restrictions. Full information about CC-BY: https://creativecommons.org/licenses/by/4.0/legalcode.
How to Cite
References
Blaese R., Culver K.W., Miller A.D., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P., Greenblatt J.J., Rosenberg S.A., Klein H., Berger M., Mullen C. A., Ramsey W.J., Muul L., Morgan R.A., Anderson W.F. (1995), T lymphocyte-directed gene therapy for ADASCID: Initial trial results after 4 years, „Science” 270: 475–480, URL = https://doi.org/10.1126/science.270.5235.475 [dostęp 07.08.2023].
Bordignon C., Notarangelo L.D., Nobili N., Ferrari G., Casorati G., Panina P., Mazzolari E., Maggioni D., Rossi C., Servida P., Ugazio A.G., Mavilio F. (1995), Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients, „Science” 270: 470–475, URL = https://doi.org/10.1126/science.270.5235.470 [dostęp 07.08.2023].
Buckland K., Gaspar H.B. (2014), Gene and cell therapy for children – New medicines, new challenges?, „Advanced Drug Delivery Reviews” 73 (100): 162–169, URL = https:// doi.org/10.1016/j.addr.2014.02.010 [dostęp 07.08.2023].
Carvalho M., Sepodes B., Martins A.P. (2017), Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework, „Frontiers in Medicine (Lausanne)” 4: 182, URL = https://doi.org/10.3389/fmed.2017.00182 [dostęp 07.08.2023].
Cavazzana-Calvo M., Fisher A. (2000), Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, „Science” 288: 669–672, URL = https://doi.org/10.1126/science.288.5466.669 [dostęp 07.08.2023].
ClinicalTrials.gov (2018), A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease, URL = https://clinicaltrials.gov/ct2/show/NCT03745287 [dostęp 18.06.2023].
Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. (2013), Multiplex genome engineering using CRISPR/Cas systems, „Science” 339: 819–823, URL = https://doi.org/10.1126/science.1231143 [dostęp 07.08.2023].
Detela G., Lodge A. (2019), EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation, „Molecular Therapy: Methods & Clinical Development” 13: 205–232, URL = https://doi.org/10.1016/j.omtm.2019.01.010 [dostęp 07.08.2023].
EMA (European Medicines Agency) (2014), Mandate of the EMA Innovation Task Force (ITF), URL = https://www.ema.europa.eu/en/documents/other/mandate-european-medicines-agency-innovation-task-force-itf_en.pdf [dostęp 01.07.2023].
European Commission (2003), EU directives. Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, „Official Journal of the European Union” L159: 46–94, URL = https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.L_.2003.159.01.0046.01.ENG&toc=OJ%3AL%3A2003%3A159%3ATOC [dostęp 07.08.2023].
European Commission (2009), Commission Directive 2009/ 120/EC of 14 September 2009 amending Directive 2001/83/ EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products, „Official Journal of the European Union” L242: 3–12, URL = https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.L_.2009.242.01.0003.01.ENG&toc=OJ%3AL%3A2009%3A242%3ATOC [dostęp 07.08.2023].
Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. (1998), Potent and specific genetic interference by double- stranded RNA in Caenorhabditis elegans, „Nature” 391: 806–811, URL = https://doi.org/10.1038/35888 [dostęp 07.08.2023].
Fry T., Shah N.N., Orentas R.J. et al. (2018), CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19- targeted CAR immunotherapy, „Nature Medicine” 24: 20–28, URL = https://doi.org/10.1038/nm.4441 [dostęp 07.08.2023].
Gastelurrutia P., Prat-Vidal C., Vives J., Coll R., Bayes-Genis A., Galvez-Monton C. (2021), Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience, „Frontiers in Cardiovascular Medicine” 8: 1-10, URL = https://doi.org/10.3389/fcvm.2021.604434 [dostęp 07.08.2023].
Gonçalves E. (2020), Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment, „The European Journal of Health Economics” 21 (3): 311–320, URL = https://doi.org/10.1007/s10198-019-01147-x [dostęp 07.08.2023].
Goradel N.H., Ghiyami-Hour F., Negahdari B., Malekshahi Z.V., Hashemzehi M., Masoudifar A., Mirzaei H. (2017), Stem Cell Therapy: A New Therapeutic Option for Cardiovascular Diseases, „Journal of Cellular Biochemistry” 119 (1): 95–104, URL = https://doi.org/10.1002/jcb.26169 [dostęp 07.08.2023].
Goula A., Gkioka V., Michalopoulos E., Katsimpoulas M., Noutsias M., Sarri F., Stavropoulos C., Kostakis A. (2020), Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine, „Journal of Clinical Medial Research” 12 (12): 780–786, URL = https://doi.org/10.14740/jocmr3964 [dostęp 07.08.2023].
Gromadzka A., Kubiczak M., Jankowska A. (2010), Terapia genowa i jej zastosowanie w leczeniu nowotworów ginekologicznych, „Ginekologia Polska” 81 (1): 50–54.
Gutt R. (1995), Rozwój klinicznej medycyny wewnętrznej i specjalności pokrewnych, [w:] Historia medycyny, T. Brzeziński (red.), PZWL, Warszawa.
Hanna E., Rémuzat C., Auquier P., Toumi M. (2016), Advanced therapy medicinal products: current and future perspectives, „Journal of Market Access & Health Policy” 4 (1): 1-10, URL = https://doi.org/10.3402/jmahp.v4.31036 [dostęp 07.08.2023].
Hildt E. (2016), Human Germline Interventions – Think First, „Frontiers in Genetics” 7 (81): 1–3, URL = https://doi.org/10.3389/fgene.2016.00081 [dostęp 07.08.2023].
Li C., Mei H., Hu Y. (2020), CAR-T Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy, „Briefings in Functional Genomics” 19 (3): 175–182, URL = https://doi.org/10.1093/bfgp/elz042 [dostęp 07.08.2023].
Maciulaitis R., D’Apote L., Buchanan A., Pioppo L., Schneider C.K. (2012), Clinical development of advanced therapy medicinal products in Europe: Evidence that regulators must be proactive, „Molecular Therapy” 20 (3): 479–482, URL = https://doi.org/10.1038/mt.2012.13 [dostęp 07.08.2023].
Maeder M., Stefanidakis M., Wilson C.J. et. al. (2019), Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10, „Nature Medicine” 25: 229–233, URL = https://doi.org/10.1038/s41591-018-0327-9 [dostęp 07.08.2023].
Mojica F., Díez-Villaseñor C., Soria E., Juez G. (2000), Biological significance of a family of regularly spaced repeats in the genomes of archaea, bacteria and mitochondria, „Molecular Microbiology” 36 (1): 244–246, URL = https://doi.org/10.1046/j.1365-2958.2000.01838.x [dostęp 07.08.2023].
Pellegrini G., Ardigò D., Milazzo G., Iotti G., Guatelli P., Pelosi D., De Luca M. (2018), Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union, „Stem Cells Translational Medicine” 7 (1): 146–154, URL = https://doi.org/10.1002/sctm.17-0003 [dostęp 07.08.2023].
Pizevska M., Kaeda J., Fritsche E., Elazaly H., Reinke P., Amini L. (2022), Advanced Therapy Medicinal Products’ Translation in Europe: A Developers’ Perspective, „Frontiers in Medicine” 9: 1-8, URL = https://doi.org/10.3389/fmed.2022.757647 [dostęp 07.08.2023].
Raje N., Berdeja J., Lin Y. et al. (2019), Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, „New England Journal of Medicine” 380 (18): 1726–1737, URL = https://doi.org/10.1056/NEJMoa1817226 [dostęp 07.08.2023].
Raper S., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.., Wilson J.M., Batshaw M.L. (2003), Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, „Molecular Genetics and Metabolism” 80 (1–2): 148–158, URL = https://doi.org/10.1016/j.ymgme.2003.08.016 [dostęp 07.08.2023].
Rosenberg S., Aebersol P., Cornetta K., Kasid A., Morgan R., Moen R., Karson E., Lotze M., Yang J., Topalian S., Merino M., Culver K., Miller D., Blaese M., Anderson F., (1990), Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction, „New England Journal of Medicine” 323: 570–578, URL = https://doi.org/10.1056/nejm199008303230904 [dostęp 07.08.2023].
Rozporządzenie 1394 (2007) – Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC, URL = https://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF [dostęp 21.01.2023].
Rzepiński T. (2019), Odkrycie środka leczniczego – dwie koncepcje rozwoju badań w zakresie farmakologii przedklinicznej, [w:] Genius Vitae. Księga pamiątkowa dedykowana panu profesorowi Marianowi Józefowi Wnukowi, S. Janeczek, Z Wróblewski, A. Starościc, (red.) Wydawnictwo KUL, Lublin: 283–301.
Rzepiński T. (2023a), Problemy i ograniczenia badań klinicznych produktów leczniczych terapii zaawansowanych (ATMP), Ekspertyza dla Stałej Rektorskiej Komisji ds. Etyki Badań Naukowych UJ, URL = https://etykabadan.komisja.uj.edu.pl/dzialalnosc/przeglady-i-ekspertyzy [dostęp 07.08.2023].
Rzepiński T. (2023b), Subjectivity of pre-test probability value: controversies over the use of Bayes’ Theorem in medical diagnosis, „Theoretical Medicine and Bioethics” 44: 301–324 (w druku), URL = https://doi.org/10.1007/s11017-023-09614-6 [dostęp 07.08.2023].
Sagar R., Götherström C., David A.L., Westgren M. (2019), Fetal stem cell transplantation and gene therapy, „Best Practice & Research Clinical Obstetrics and Gynaecology” 58: 142–153, URL = https://doi.org/10.1016/j.bpobgyn.2019.02.007 [dostęp 07.08.2023].
Sanzenbacher R., Dwenger A., Schuessler-Lenz M., Cichutek K., Flory E. (2007), European regulation tackles tissue-engineering, „Nature Biotechnology” 25 (10): 1089–1091, URL = https://doi.org/10.1038/nbt1007-1089 [dostęp 07.08.2023].
Susanibar-Adaniya S.P., Cohen A., Garfall A.L. (2019), Chimeric antigen receptor T cell immunotherapy for multiple myeloma: a review of current data and potential clinical applications, „American Journal of Hematology” 94 (1): 28–33, URL = https://doi.org/10.1002/ajh.25428 [dostęp 07.08.2023].
Trounson A., McDonald C. (2015), Stem Cell Therapies in Clinical Trials: Progress and Challenges, „Cell Stem Cell” 17 (1): 11–22, URL = https://doi.org/10.1016/j.stem.2015.06.007 [dostęp 07.08.2023].
Uddin F., Rudin C.M., Sen T. (2020), CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future Fathema, „Frontiers in Oncology” 10: 1-17, URL = https://doi.org/10.3389/fonc.2020.01387 [dostęp 07.08.2023].
Zobel A., Heelan B. (2017), Regulatory, clinical and logistics challenges of ATMPs in clinical research, „European Pharmaceutical Review” 4, URL = https://www.europeanpharmaceuticalreview.com/article/81122/regulatory-clinical-and-logistics-challenges-of-advanced-therapy-medicinal-products-atmps-in-clinical-research/ [dostęp 08.07.2023].